デフォルト表紙
市場調査レポート
商品コード
1505987

パーキンソン病関連認知症:市場分析、疫学、市場予測 (2034年)

Parkinson's Disease Related Dementia - Market Insight, Epidemiology, and Market Forecast - 2034


出版日
発行
DelveInsight
ページ情報
英文 200 Pages
納期
2~10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
パーキンソン病関連認知症:市場分析、疫学、市場予測 (2034年)
出版日: 2024年06月01日
発行: DelveInsight
ページ情報: 英文 200 Pages
納期: 2~10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の主要7ヶ国 - 米国、欧州主要5ヶ国 (EU5:フランス・ドイツ・イタリア・スペイン・英国)、日本 - におけるパーキンソン病関連認知症の疫学的動向と今後の市場見通しについて分析し、疾患の概要や市場の基本構造、現在の治療法とアンメットニーズ、有病者数の動向見通し、上市済み/治験中の治療薬のプロファイル、世界全体/各国の市場規模 (2020年~2034年)、主な市場促進・抑制要因、といった情報を取りまとめてお届けいたします。

調査概要

  • パーキンソン病関連認知症市場は今後数年間で、この疾患に対する認識の高まりと、世界全体の医療費増加により変化します。
  • 企業や研究機関は、パーキンソン病関連認知症の研究開発に影響を与える可能性のある課題を評価し、その機会を探るべく取り組んでいます。開発中の治療法は、病態を治療/改善するための新規アプローチに焦点を当てています。
  • 主要企業はパーキンソン病関連認知症の治療法開発に関与しています。新たな治療法の上市は、パーキンソン病関連認知症市場に大きな影響を与えるでしょう。
  • 疾患の病態のより深い理解が、パーキンソン病関連認知症の新規治療薬の開発にも貢献します。
  • 異なる開発段階 (第III相および第II相) におけるパイプライン資産の詳細な分析や新たな動向、各々のパイプライン製品の比較分析 (詳細な臨床プロファイル、主要なクロス競合、製品の発売日・開発活動などを含む) といった情報が、研究開発活動の全体的なシナリオを識別することにより、治療ポートフォリオに関する意思決定プロセスで、クライアントをサポートします。

目次

第1章 主な考察

第2章 パーキンソン病関連認知症:エグゼクティブサマリー

第3章 パーキンソン病関連認知症:競合情報分析

第4章 パーキンソン病関連認知症:市場概要

  • パーキンソン病関連認知症の全体的な市場シェア (%、2020年)
  • パーキンソン病関連認知症の全体的な市場シェア (%、2034年)

第5章 パーキンソン病関連認知症:疾患の背景と概要

  • イントロダクション
  • 兆候と症状
  • 病態生理
  • 危険因子
  • 診断方法

第6章 ペイシェント・ジャーニー

第7章 パーキンソン病関連認知症の疫学と患者人口

  • 疫学的動向:主な調査結果
  • 仮定と理論的根拠:主要7ヶ国
  • 疫学シナリオ:主要7ヶ国
    • パーキンソン病関連認知症:主要7ヶ国における疫学シナリオ (2020年~2034年)
  • 米国の疫学
    • 米国のパーキンソン病関連認知症の疫学シナリオ (2020年~2034年)
  • 欧州主要5ヶ国 (5EU) の疫学:国別
    • ドイツの疫学
    • フランスの疫学
    • イタリアの疫学
    • スペインの疫学
    • 英国の疫学
    • 日本の疫学

第8章 治療アルゴリズム、現在の治療、医療行為

  • パーキンソン病関連認知症の治療・管理方法
  • パーキンソン病関連認知症の治療アルゴリズム

第9章 アンメットニーズ

第10章 パーキンソン病関連認知症治療薬の主要評価項目

第11章 上市済み製品

  • 主要7ヶ国の上市済み製品の一覧
  • 薬剤の名称:企業名
    • 製品概要
    • 規制のマイルストーン
    • その他の開発活動
    • 重要な治験
    • 重要な治験:概要

第12章 新たな治療薬

  • キークロス
  • 薬剤の名称:企業名
    • 製品概要
    • その他の開発活動
    • 臨床開発
    • 安全性と有効性
    • 製品プロファイル

第13章 パーキンソン病関連認知症:主要7ヶ国の市場分析

  • 主な調査結果
  • パーキンソン病関連認知症の市場規模:主要7ヶ国
  • パーキンソン病関連認知症の市場規模:主要7ヶ国、治療薬別

第14章 属性分析

第15章 主要7ヶ国:市場の将来展望

  • 米国の市場規模
    • 米国のパーキンソン病関連認知症の全体的な市場規模
    • 米国の市場規模:治療薬別
  • 欧州主要5ヶ国 (EU5) 市場:市場規模と将来展望
  • ドイツの市場規模
    • ドイツのパーキンソン病関連認知症の全体的な市場規模
    • ドイツの市場規模:治療薬別
  • フランスの市場規模
  • イタリアの市場規模
  • スペインの市場規模
  • 英国の市場規模
    • 英国のパーキンソン病関連認知症の全体的な市場規模
    • 英国の市場規模:治療薬別
  • 日本市場:将来展望
    • 日本の市場規模

第16章 パーキンソン病関連認知症のアクセスと償還の概要

第17章 KOLの見解

第18章 市場促進要因

第19章 市場阻害要因

第20章 付録

第21章 DelveInsightのサービス内容

第22章 免責事項

第23章 DelveInsightについて

図表

List of Tables

  • Table 1: 7MM Parkinson's Disease Related Dementia Epidemiology (2020-2034)
  • Table 2: 7MM Parkinson's Disease Related Dementia Diagnosed and Treatable Cases (2020-2034)
  • Table 3: Parkinson's Disease Related Dementia Epidemiology in the United States (2020-2034)
  • Table 4: Parkinson's Disease Related Dementia Diagnosed and Treatable Cases in the United States (2020-2034)
  • Table 5: Parkinson's Disease Related Dementia Epidemiology in Germany (2020-2034)
  • Table 6: Parkinson's Disease Related Dementia Diagnosed and Treatable Cases in Germany (2020-2034)
  • Table 7: Parkinson's Disease Related Dementia Epidemiology in France (2020-2034)
  • Table 8: Parkinson's Disease Related Dementia Diagnosed and Treatable Cases in France (2020-2034)
  • Table 9: Parkinson's Disease Related Dementia Epidemiology in Italy (2020-2034)
  • Table 10: Parkinson's Disease Related Dementia Diagnosed and Treatable Cases in Italy (2020-2034)
  • Table 11: Parkinson's Disease Related Dementia Epidemiology in Spain (2020-2034)
  • Table 12: Parkinson's Disease Related Dementia Diagnosed and Treatable Cases in Spain (2020-2034)
  • Table 13: Parkinson's Disease Related Dementia Epidemiology in the UK (2020-2034)
  • Table 14: Parkinson's Disease Related Dementia Diagnosed and Treatable Cases in the UK (2020-2034)
  • Table 15: Parkinson's Disease Related Dementia Epidemiology in Japan (2020-2034)
  • Table 16: Parkinson's Disease Related Dementia Diagnosed and Treatable Cases in Japan (2020-2034)
  • Table 17: Drug Name, Clinical Trials by Recruitment status
  • Table 18: Drug Name, Clinical Trials by Zone
  • Table 19: Total Seven Major Market Size in USD, Million (2020-2034)
  • Table 20: Region-wise Market Size in USD, Million (2020-2034)
  • Table 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
  • Table 22: United States Market Size in USD, Million (2020-2034)
  • Table 23: United States Market Size by Therapy in USD, Million (2020-2034)
  • Table 24: Germany Market Size in USD, Million (2020-2034)
  • Table 25: Germany Market Size by Therapy in USD, Million (2020-2034)
  • Table 26: France Market Size in USD, Million (2020-2034)
  • Table 27: France Market Size by Therapy in USD, Million (2020-2034)
  • Table 28: Italy Market Size in USD, Million (2020-2034)
  • Table 29: Italy Market Size by Therapy in USD, Million (2020-2034)
  • Table 30: Spain Market Size in USD, Million (2020-2034)
  • Table 31: Spain Market Size by Therapy in USD, Million (2020-2034)
  • Table 32: United Kingdom Market Size in USD, Million (2020-2034)
  • Table 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
  • Table 34: Japan Market Size in USD, Million (2020-2034)
  • Table 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of tables is not exhaustive; the final content may vary

List of Figures

  • Figure 1: 7MM Parkinson's Disease Related Dementia Epidemiology (2020-2034)
  • Figure 2: 7MM Parkinson's Disease Related Dementia Diagnosed and Treatable Cases (2020-2034)
  • Figure 3: Parkinson's Disease Related Dementia Epidemiology in the United States (2020-2034)
  • Figure 4: Parkinson's Disease Related Dementia Diagnosed and Treatable Cases in the United States (2020-2034)
  • Figure 5: Parkinson's Disease Related Dementia Epidemiology in Germany (2020-2034)
  • Figure 6: Parkinson's Disease Related Dementia Diagnosed and Treatable Cases in Germany (2020-2034)
  • Figure 7: Parkinson's Disease Related Dementia Epidemiology in France (2020-2034)
  • Figure 8: Parkinson's Disease Related Dementia Diagnosed and Treatable Cases in France (2020-2034)
  • Figure 9: Parkinson's Disease Related Dementia Epidemiology in Italy (2020-2034)
  • Figure 10: Parkinson's Disease Related Dementia Diagnosed and Treatable Cases in Italy (2020-2034)
  • Figure 11: Parkinson's Disease Related Dementia Epidemiology in Spain (2020-2034)
  • Figure 12: Parkinson's Disease Related Dementia Diagnosed and Treatable Cases in Spain (2020-2034)
  • Figure 13: Parkinson's Disease Related Dementia Epidemiology in the UK (2020-2034)
  • Figure 14: Parkinson's Disease Related Dementia Diagnosed and Treatable Cases in the UK (2020-2034)
  • Figure 15: Parkinson's Disease Related Dementia Epidemiology in Japan (2020-2034)
  • Figure 16: Parkinson's Disease Related Dementia Diagnosed and Treatable Cases in Japan (2020-2034)
  • Figure 17: Drug Name, Clinical Trials by Recruitment status
  • Figure 18: Drug Name, Clinical Trials by Zone
  • Figure 19: Total Seven Major Market Size in USD, Million (2020-2034)
  • Figure 20: Region-wise Market Size in USD, Million (2020-2034)
  • Figure 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
  • Figure 22: United States Market Size in USD, Million (2020-2034)
  • Figure 23: United States Market Size by Therapy in USD, Million (2020-2034)
  • Figure 24: Germany Market Size in USD, Million (2020-2034)
  • Figure 25: Germany Market Size by Therapy in USD, Million (2020-2034)
  • Figure 26: France Market Size in USD, Million (2020-2034)
  • Figure 27: France Market Size by Therapy in USD, Million (2020-2034)
  • Figure 28: Italy Market Size in USD, Million (2020-2034)
  • Figure 29: Italy Market Size by Therapy in USD, Million (2020-2034)
  • Figure 30: Spain Market Size in USD, Million (2020-2034)
  • Figure 31: Spain Market Size by Therapy in USD, Million (2020-2034)
  • Figure 32: United Kingdom Market Size in USD, Million (2020-2034)
  • Figure 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
  • Figure 34: Japan Market Size in USD, Million (2020-2034)
  • Figure 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of figures is not exhaustive; the final content may vary

目次
Product Code: DIMI1405

DelveInsight's "Parkinson's Disease Related Dementia - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Parkinson's Disease Related Dementia, historical and forecasted epidemiology as well as the Parkinson's Disease Related Dementia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Parkinson's Disease Related Dementia market report provides current treatment practices, emerging drugs, Parkinson's Disease Related Dementia market share of the individual therapies, current and forecasted Parkinson's Disease Related Dementia market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Parkinson's Disease Related Dementia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2020-2034

Parkinson's Disease Related Dementia Disease Understanding and Treatment Algorithm

The DelveInsight Parkinson's Disease Related Dementia market report gives a thorough understanding of the Parkinson's Disease Related Dementia by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Parkinson's Disease Related Dementia.

Treatment

It covers the details of conventional and current medical therapies available in the Parkinson's Disease Related Dementia market for the treatment of the condition. It also provides Parkinson's Disease Related Dementia treatment algorithms and guidelines in the United States, Europe, and Japan.

Parkinson's Disease Related Dementia Epidemiology

The Parkinson's Disease Related Dementia epidemiology division provide insights about historical and current Parkinson's Disease Related Dementia patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Parkinson's Disease Related Dementia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Parkinson's Disease Related Dementia Epidemiology

The epidemiology segment also provides the Parkinson's Disease Related Dementia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Parkinson's Disease Related Dementia Drug Chapters

Drug chapter segment of the Parkinson's Disease Related Dementia report encloses the detailed analysis of Parkinson's Disease Related Dementia marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Parkinson's Disease Related Dementia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Parkinson's Disease Related Dementia treatment.

Parkinson's Disease Related Dementia Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Parkinson's Disease Related Dementia treatment.

Parkinson's Disease Related Dementia Market Outlook

The Parkinson's Disease Related Dementia market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Parkinson's Disease Related Dementia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Parkinson's Disease Related Dementia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Parkinson's Disease Related Dementia market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Parkinson's Disease Related Dementia market in 7MM.

The United States Market Outlook

This section provides the total Parkinson's Disease Related Dementia market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Parkinson's Disease Related Dementia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Parkinson's Disease Related Dementia market size and market size by therapies in Japan is also mentioned.

Parkinson's Disease Related Dementia Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Parkinson's Disease Related Dementia market or expected to get launched in the market during the study period 2020-2034. The analysis covers Parkinson's Disease Related Dementia market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Parkinson's Disease Related Dementia Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Parkinson's Disease Related Dementia key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Parkinson's Disease Related Dementia emerging therapies.

Reimbursement Scenario in Parkinson's Disease Related Dementia

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Parkinson's Disease Related Dementia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Parkinson's Disease Related Dementia market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Parkinson's Disease Related Dementia Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Parkinson's Disease Related Dementia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Parkinson's Disease Related Dementia epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Parkinson's Disease Related Dementia are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Parkinson's Disease Related Dementia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Parkinson's Disease Related Dementia market

Report Highlights:

  • In the coming years, Parkinson's Disease Related Dementia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Parkinson's Disease Related Dementia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Parkinson's Disease Related Dementia. Launch of emerging therapies will significantly impact the Parkinson's Disease Related Dementia market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Parkinson's Disease Related Dementia
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Parkinson's Disease Related Dementia Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Parkinson's Disease Related Dementia Pipeline Analysis
  • Parkinson's Disease Related Dementia Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Parkinson's Disease Related Dementia Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Parkinson's Disease Related Dementia Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Parkinson's Disease Related Dementia Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Parkinson's Disease Related Dementia market share (%) distribution in 2020 and how it would look like in 2034?
  • What would be the Parkinson's Disease Related Dementia total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Parkinson's Disease Related Dementia market size during the forecast period (2024-2034)?
  • At what CAGR, the Parkinson's Disease Related Dementia market is expected to grow in 7MM during the forecast period (2020-2034)?
  • What would be the Parkinson's Disease Related Dementia market outlook across the 7MM during the forecast period (2020-2034)?
  • What would be the Parkinson's Disease Related Dementia market growth till 2032, and what will be the resultant market Size in the year 2034?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Parkinson's Disease Related Dementia?
  • What is the historical Parkinson's Disease Related Dementia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Parkinson's Disease Related Dementia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Parkinson's Disease Related Dementia?
  • Out of all 7MM countries, which country would have the highest prevalent population of Parkinson's Disease Related Dementia during the forecast period (2020-2034)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Parkinson's Disease Related Dementia treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Parkinson's Disease Related Dementia in the USA, Europe, and Japan?
  • What are the Parkinson's Disease Related Dementia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Parkinson's Disease Related Dementia?
  • How many therapies are developed by each company for Parkinson's Disease Related Dementia treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Parkinson's Disease Related Dementia treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Parkinson's Disease Related Dementia therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Parkinson's Disease Related Dementia and their status?
  • What are the key designations that have been granted for the emerging therapies for Parkinson's Disease Related Dementia?
  • What are the global historical and forecasted market of Parkinson's Disease Related Dementia?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Parkinson's Disease Related Dementia market
  • To understand the future market competition in the Parkinson's Disease Related Dementia market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Parkinson's Disease Related Dementia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Parkinson's Disease Related Dementia market
  • To understand the future market competition in the Parkinson's Disease Related Dementia market

Table of Contents

1. Key Insights

2. Executive Summary of Parkinson's Disease Related Dementia

3. Competitive Intelligence Analysis for Parkinson's Disease Related Dementia

4. Parkinson's Disease Related Dementia: Market Overview at a Glance

  • 4.1. Parkinson's Disease Related Dementia Total Market Share (%) Distribution in 2020
  • 4.2. Parkinson's Disease Related Dementia Total Market Share (%) Distribution in 2034

5. Parkinson's Disease Related Dementia: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Parkinson's Disease Related Dementia Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Parkinson's Disease Related Dementia Epidemiology Scenario in the 7MM (2020-2034)
  • 7.4. United States Epidemiology
    • 7.4.1. Parkinson's Disease Related Dementia Epidemiology Scenario in the United States (2020-2034)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Parkinson's Disease Related Dementia Epidemiology Scenario in Germany (2020-2034)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Parkinson's Disease Related Dementia Epidemiology Scenario in France (2020-2034)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Parkinson's Disease Related Dementia Epidemiology Scenario in Italy (2020-2034)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Parkinson's Disease Related Dementia Epidemiology Scenario in Spain (2020-2034)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Parkinson's Disease Related Dementia Epidemiology Scenario in the United Kingdom (2020-2034)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Parkinson's Disease Related Dementia Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Parkinson's Disease Related Dementia Treatment and Management
  • 8.2. Parkinson's Disease Related Dementia Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Parkinson's Disease Related Dementia Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Parkinson's Disease Related Dementia: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Parkinson's Disease Related Dementia Market Size in 7MM
  • 13.3. Parkinson's Disease Related Dementia Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Parkinson's Disease Related Dementia Total Market Size in the United States
    • 15.1.2. Parkinson's Disease Related Dementia Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Parkinson's Disease Related Dementia Total Market Size in Germany
    • 15.3.2. Parkinson's Disease Related Dementia Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Parkinson's Disease Related Dementia Total Market Size in France
    • 15.4.2. Parkinson's Disease Related Dementia Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Parkinson's Disease Related Dementia Total Market Size in Italy
    • 15.5.2. Parkinson's Disease Related Dementia Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Parkinson's Disease Related Dementia Total Market Size in Spain
    • 15.6.2. Parkinson's Disease Related Dementia Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Parkinson's Disease Related Dementia Total Market Size in the United Kingdom
    • 15.7.2. Parkinson's Disease Related Dementia Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Parkinson's Disease Related Dementia Total Market Size in Japan
    • 15.8.3. Parkinson's Disease Related Dementia Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Parkinson's Disease Related Dementia

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.